Last updated: November 9, 2026
Vactosertib, also known as TEW-7197, is an oral small-molecule inhibitor of transforming growth factor beta receptor I, or TGF-βRI. MedPacto is developing the drug for myelodysplastic syndromes, colorectal cancer and other advanced solid tumors, primarily in combination with existing therapies. Through June 2024, vactosertib remained investigational, with no FDA approval, New Drug Application, Biologics License Application or Orange Book listing identified. Its commercial value depends on whether MedPacto can convert biomarker-driven combination data into a registrational result.
The most credible initial opportunity is relapsed or refractory myelodysplastic syndromes, where vactosertib has been evaluated with decitabine. Solid-tumor programs involving pembrolizumab remain higher-risk because they require proof that TGF-β pathway inhibition improves outcomes in immunotherapy-resistant disease.
What is vactosertib and how does it work?
Vactosertib inhibits TGF-β receptor I, also known as activin receptor-like kinase 5, or ALK5. TGF-β signaling can promote immune suppression, tumor-cell invasion, stromal remodeling and resistance to cancer treatment. The drug is intended to reduce those effects and improve the activity of chemotherapy or immune checkpoint inhibitors.
Vactosertib is an oral targeted therapy rather than a biologic. Its regulatory path would therefore be an NDA under the conventional small-molecule framework, not a BLA or biosimilar pathway.
| Attribute |
Vactosertib |
| Generic name |
Vactosertib |
| Development code |
TEW-7197 |
| Modality |
Oral small-molecule kinase inhibitor |
| Primary target |
TGF-β receptor I / ALK5 |
| Developer |
MedPacto |
| Lead disease areas |
Myelodysplastic syndromes, colorectal cancer, advanced solid tumors |
| Principal combinations |
Decitabine, pembrolizumab and chemotherapy |
| FDA status |
Investigational |
| Approval status |
Not approved through June 2024 |
| Orange Book status |
No listed product identified |
| Biosimilar exposure |
Not applicable |
| Main competitive risk |
Clinical differentiation and generic combination competition |
What is the current clinical development status of vactosertib?
Vactosertib has advanced through early- and mid-stage studies, but public evidence does not establish a completed pivotal trial supporting registration. The program has focused on two development strategies.
Myelodysplastic syndromes
MedPacto has studied vactosertib with decitabine in patients with myelodysplastic syndromes, including patients with disease that is resistant to or has relapsed after hypomethylating-agent treatment. This is the program’s clearest regulatory opportunity because it addresses a defined hematologic population with limited treatment options.
Publicly reported studies have assessed response rate, transfusion independence, disease progression and survival. The combination approach is commercially relevant because decitabine is already used in MDS and gives vactosertib a potential positioning as an add-on therapy rather than a replacement for standard treatment.
The main development risks are:
- Whether responses are durable enough for accelerated or traditional approval.
- Whether the combination improves overall survival or clinically meaningful hematologic outcomes.
- Whether the safety profile is acceptable in patients with cytopenias and marrow failure.
- Whether regulators require a randomized confirmatory trial.
ClinicalTrials.gov lists studies of vactosertib in MDS and provides the most reliable public record for enrollment, endpoints and study status (National Library of Medicine, n.d.-a).
Advanced solid tumors
The solid-tumor program has evaluated vactosertib with pembrolizumab and other antineoplastic regimens. The scientific rationale is that TGF-β inhibition may reverse an immunosuppressive tumor microenvironment and increase sensitivity to PD-1 blockade.
The principal development questions are:
- Which tumor types have sufficient TGF-β pathway dependence?
- Which patients should be selected using biomarkers?
- Can vactosertib improve objective response or progression-free survival over pembrolizumab alone?
- Does the combination create additive toxicity, particularly gastrointestinal, hepatic or hematologic toxicity?
Clinical studies have included patients with advanced solid tumors and colorectal cancer. These programs are earlier and commercially less predictable than the MDS program because pembrolizumab combinations face a high evidentiary bar and substantial competition.
Development timeline
| Period |
Development event |
| Pre-2020 |
Early clinical development of vactosertib as a TGF-βRI inhibitor |
| 2020 |
MedPacto and Merck announced a clinical collaboration to evaluate vactosertib with pembrolizumab |
| 2020-2022 |
Clinical studies expanded into MDS and advanced solid tumors |
| 2022-2024 |
Combination studies continued in hematologic and solid-tumor indications |
| June 2024 |
No FDA approval or publicly identified pivotal approval filing |
The Merck relationship was a clinical collaboration, not a disclosed acquisition or broad commercial license. Public announcements did not establish that Merck had an option to commercialize vactosertib.
What is the FDA regulatory status of vactosertib?
Vactosertib is not an FDA-approved drug. No FDA-approved label, prescribing information, safety communication or commercial product code was identified through June 2024.
MedPacto has pursued U.S. clinical development and has reported regulatory interactions relating to vactosertib in MDS and cancer combinations. The FDA’s orphan-drug database is the relevant source for determining whether a specific indication has received orphan designation. Orphan designation does not establish efficacy or guarantee approval, but it can provide tax credits, fee benefits, protocol assistance and potential seven-year U.S. market exclusivity after approval (U.S. Food and Drug Administration, n.d.-a).
Vactosertib has no biologic license, so biosimilar competition is not the relevant loss-of-exclusivity issue. If approved, the product would face small-molecule generic competition after applicable patents and regulatory exclusivity expire.
What patents protect vactosertib and when could it lose exclusivity?
Vactosertib’s protection is expected to rely on a combination of composition-of-matter, pharmaceutical composition, treatment-method and combination-therapy patent families. Public company disclosures describe intellectual-property protection, but the public record does not provide a single definitive expiration date that can be assigned to every relevant U.S. claim.
The commercial patent analysis should distinguish four layers:
Composition-of-matter patents
These are the most valuable rights because they protect the active molecule itself. A valid, unexpired composition patent can block generic vactosertib regardless of the approved indication.
Formulation patents
Vactosertib is an oral small molecule. Formulation claims may cover tablets, solid dispersions, salt forms, excipient systems, dissolution profiles or stability improvements. Such claims are usually weaker than composition claims because a generic applicant may design around them.
Method-of-use patents
Method claims may cover treatment of MDS, colorectal cancer, pancreatic cancer or other tumors, including use with decitabine, pembrolizumab or chemotherapy. These patents can support patent-listing and litigation strategies, but they do not necessarily prevent a generic company from selling the molecule for an unpatented indication.
Combination patents
Combination claims covering vactosertib with PD-1 inhibitors or hypomethylating agents could become commercially important if the FDA approves only a combination regimen. Their value depends on claim breadth, clinical adoption and the ability to enforce the claims against a generic or competing product.
No Orange Book listing was identified because no vactosertib product has FDA approval. Until approval, there is no Orange Book patent dispute and no conventional Paragraph IV litigation tied to an approved vactosertib product.
Are there Paragraph IV challenges, patent litigation or settlements?
No material public Paragraph IV challenge, ANDA litigation proceeding or patent settlement involving an approved vactosertib product was identified through June 2024.
That result follows from the drug’s development stage. Paragraph IV litigation normally begins after an innovator lists patents in the Orange Book and a generic applicant files an ANDA with a Paragraph IV certification. Vactosertib has not reached that stage.
The most likely future dispute structure would be:
- A generic challenges composition patents through Paragraph IV certification.
- MedPacto or a commercial partner brings a patent-infringement action.
- The parties litigate formulation, metabolite, salt or method-of-use claims.
- A settlement could defer generic entry while permitting an earlier launch date.
No public settlement agreement establishing a vactosertib generic-entry date was identified.
How strong is the vactosertib patent estate?
The estate appears strategically useful but commercially unproven. Its strength will depend on the status of composition claims and the remaining patent term at the time of approval.
| Patent layer |
Expected commercial value |
Key vulnerability |
| Composition of matter |
High |
Validity, written description, obviousness and expiration |
| Formulation |
Moderate |
Design-around options |
| MDS treatment method |
Moderate to high |
Label restrictions and off-label prescribing |
| Pembrolizumab combination |
Moderate |
Narrow claims and dependence on combination approval |
| Manufacturing process |
Moderate |
Alternative synthetic routes |
| Biomarker-selected use |
Potentially high |
Patient-selection limitations and proof of biomarker utility |
Manufacturing patents could raise switching costs if vactosertib requires a specialized intermediate, difficult crystallization step or tightly controlled impurity profile. They are less likely to prevent generic entry than a valid composition patent because generic manufacturers can often develop an alternative process.
What is the market opportunity for vactosertib?
The near-term commercial opportunity is concentrated in MDS. The broader solid-tumor opportunity is larger in patient population but less predictable because it depends on clinical differentiation in crowded treatment markets.
MDS opportunity
MDS is a relatively small oncology market compared with colorectal or lung cancer, but treatment is specialized and patients often require long-term management. Existing therapies include azacitidine, decitabine, oral decitabine/cedazuridine and disease-specific agents such as luspatercept in selected populations.
A vactosertib-plus-decitabine product could be priced as a specialty oncology add-on. Its commercial value would depend on whether the combination:
- Produces meaningful responses after hypomethylating-agent failure.
- Reduces transfusion burden.
- Extends survival.
- Gains an orphan indication.
- Avoids severe additive cytopenias.
- Secures reimbursement for combination use.
Solid-tumor opportunity
The addressable population is larger, but the competitive environment is more difficult. Pembrolizumab combinations are evaluated across nearly every major tumor type. Vactosertib would need a differentiated biomarker, superior efficacy in a resistant population or a clinically meaningful survival benefit.
The most plausible commercial positioning would be in tumors with high TGF-β activity or an immunologically excluded microenvironment. Without validated patient selection, the drug risks becoming an undifferentiated immuno-oncology combination agent.
What is the projected revenue for vactosertib?
No reliable public consensus forecast or company revenue guidance establishes a validated sales figure. A scenario-based projection is more appropriate than a point estimate.
| Scenario |
Development outcome |
Indicative peak annual sales |
| Failure or prolonged development |
No approval or approval delayed beyond the decade |
$0-$25 million |
| MDS-only approval |
Niche approval with moderate uptake |
$75-$250 million |
| MDS approval plus one solid-tumor label |
Specialty oncology product with combination use |
$250-$600 million |
| Broad solid-tumor success |
Biomarker-supported use across several tumors |
$600 million-$1.2 billion |
These ranges are analytical scenarios, not company guidance. The MDS-only case is the most defensible base case if the combination shows reproducible efficacy and receives a commercially viable label. The high case requires successful expansion into solid tumors and a partner capable of global oncology commercialization.
Revenue would likely be split between product sales and partnership economics. A licensing transaction could increase development speed but reduce MedPacto’s share of net sales through royalties, milestones or regional profit sharing. The disclosed Merck collaboration did not establish such commercial economics.
How does vactosertib compare with competing drugs?
Vactosertib does not currently compete as an approved monotherapy. Its principal competitors are established treatments used in the same disease settings.
| Market |
Existing alternatives |
Vactosertib’s potential advantage |
Main disadvantage |
| MDS |
Azacitidine, decitabine, oral decitabine/cedazuridine, luspatercept in selected patients |
Oral targeted mechanism and possible activity after hypomethylating-agent failure |
Combination toxicity and unproven survival benefit |
| Colorectal cancer |
Chemotherapy, anti-VEGF therapy, anti-EGFR therapy, immunotherapy in selected tumors |
Potential restoration of immune sensitivity |
Highly competitive and biomarker-dependent |
| Advanced solid tumors |
PD-1/PD-L1 inhibitors and targeted combinations |
TGF-β pathway modulation |
Requires proof of incremental benefit over checkpoint therapy |
| Relapsed hematologic disease |
Salvage chemotherapy, targeted agents and clinical trials |
Novel mechanism |
Small patient population and fragile patients |
What generic launch risks exist?
Generic entry is unlikely before approval because there is no marketed reference product. Once approved, the risk profile would depend on the patent term and the breadth of any approved combination label.
The highest-risk launch scenario is a generic challenge to a composition patent near the end of its term. A lower-risk scenario for MedPacto would involve a long-lived composition patent supported by separate formulation and method-of-use claims. The company could also seek pediatric exclusivity, orphan-drug exclusivity or other regulatory protections, although those protections would not replace a strong composition patent.
For vactosertib, biosimilar risk is immaterial. The relevant risks are generic substitution, combination-product reimbursement and competing TGF-β pathway inhibitors.
Key Takeaways
- Vactosertib is an investigational oral TGF-βRI inhibitor developed by MedPacto.
- The leading commercial indication is MDS, particularly in combination with decitabine.
- Solid-tumor programs with pembrolizumab expand the opportunity but carry higher clinical and regulatory risk.
- Vactosertib had no FDA approval, Orange Book listing or Paragraph IV litigation through June 2024.
- No validated public revenue consensus exists. A reasonable scenario range is $75 million to $600 million in peak annual sales if the drug reaches approval, with upside above $1 billion requiring broad solid-tumor success.
- Patent value will depend primarily on composition-of-matter protection, remaining term and the scope of combination-use claims.
- Merck’s relationship was publicly described as a clinical collaboration, not a disclosed commercial license.
FAQs
Has vactosertib been approved by the FDA?
No. Vactosertib remained investigational through June 2024 and had no FDA-approved label.
Is vactosertib a TGF-beta inhibitor?
Yes. It is an oral inhibitor of TGF-β receptor I, also called ALK5.
Is vactosertib being developed for myelodysplastic syndromes?
Yes. MDS is one of the principal development areas, with studies evaluating vactosertib in combination with decitabine.
Is there a generic version of vactosertib?
No. There is no approved reference product or marketed generic vactosertib product.
Does pembrolizumab have a commercial license for vactosertib?
Public disclosures describe a clinical collaboration between MedPacto and Merck to evaluate vactosertib with pembrolizumab. They do not establish a broad commercial license or a disclosed right for Merck to commercialize the drug.
References
-
ClinicalTrials.gov. (n.d.-a). Study of vactosertib in patients with myelodysplastic syndrome. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
ClinicalTrials.gov. (n.d.-b). Vactosertib and pembrolizumab in patients with advanced solid tumors. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
MedPacto, Inc. (2020). MedPacto and Merck announce clinical collaboration to evaluate vactosertib in combination with pembrolizumab. Company press release.
-
U.S. Food and Drug Administration. (n.d.-a). Orphan drug designations and approvals. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
MedPacto, Inc. (2024). Annual report and regulatory filings. Korea Exchange and Financial Supervisory Service.